---
schema_version: "secwatch.filing_event.v1"
accession: "0001145197-23-000019"
form_type: "8-K"
ticker: "PODD"
cik: "0001145197"
company_name: "INSULET CORP"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T01:32:24.666682+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Insulet FY2022 revenue $1.3B (+19% YoY); Q4 revenue $369.7M (+20%); beats guidance; adjusted EPS $1.28

## Summary
- Full year 2022 revenue $1.3B, up 18.8% (22.2% constant currency), exceeding guidance of 18-19% constant currency.
- Omnipod revenue $1.2B (+23.4%); U.S. Omnipod $884.8M (+35.8%); International $363.0M (+0.9% reported, +12.1% constant currency).
- GAAP net income $4.6M ($0.07 diluted EPS); adjusted net income $91.1M ($1.28 diluted EPS) excluding $57.9M MDC charge, $25.2M legal costs, $3.4M CEO transition costs.
- Gross margin 61.7% (down 670 bps); adjusted gross margin 66.2% excluding $57.9M charge for voluntary medical device correction notices for Omnipod DASH PDMs and Omnipod 5 Controllers.
- Q4 2022 revenue $369.7M (+20.1% reported, +22.6% constant currency); U.S. Omnipod revenue $276.2M (+45.0%).

## SEC filing metadata
- accession: 0001145197-23-000019
- form_type: 8-K
- ticker: PODD
- cik: 0001145197
- company_name: INSULET CORP
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000019/0001145197-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000019/podd-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001145197-23-000019
- JSON: https://secwatch.observer/filing/0001145197-23-000019.json
- Plain text: https://secwatch.observer/filing/0001145197-23-000019.txt

## Key facts
- Earnings Releases
  INSULET CORP reported the full year ended December 31, 2022 results: revenue $1.3 billion, net income $4.6 million, EPS $0.07 per diluted share.
  - Period: the full year ended December 31, 2022
  - Revenue: $1.3 billion
  - Net income: $4.6 million
  - EPS: $0.07 per diluted share
  - Result: reported results
  source text: Full year 2022 revenue of $1.3 billion, up 18.8%, or 22.2% in constant currency, compared to $1.1 billion in the prior year, exceeds the guidance range of 18% to 19% in constant currency ◦ Total Omnipod revenue of $1.2 billion, an increase of 23.4%, or 27.0% in constant currency ◦ U.S. Omnipod revenue of $884.8 million, an increase of 35.8% ◦ International Omnipod revenue of $363.0 million, an increase of 0.9%, or 12.1% in constant currency ◦ Drug Delivery revenue of $57.5 million, a decrease of 34.2% • Gross margin of 61.7%, down 670 basis points. Adjusted gross margin 1 of 66.2% excludes a charge of $57.9 million associated with the voluntary medical device correction (MDC) notices issued to replace Omnipod DASH ® Personal Diabetes Managers (PDMs) and Omnipod ® 5 Automated Insulin Delivery system (Omnipod 5) Controllers • Operating income of $37.6 million, or 2.9% of revenue, compared to $126.0 million, or 11.5% of revenue, in the prior year. Adjusted operating income 1 of $124.1 mil
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000019/0001145197-23-000019-index.htm
- Earnings Releases
  INSULET CORP reported the fourth quarter ended December 31, 2022 results: revenue $369.7 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $369.7 million
  - Result: reported results
  source text: Fourth quarter 2022 revenue of $369.7 million, up 20.1%, or 22.6% in constant currency, compared to $307.7 million in the prior year, exceeds the guidance range of 11% to 14% in constant currency
  evidence_url: https://www.sec.gov/Archives/edgar/data/1145197/000114519723000019/0001145197-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.